

**SH3PXD2A Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP16560a****Specification**

---

**SH3PXD2A Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [Q5TCZ1](#)**SH3PXD2A Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 9644**Other Names**

SH3 and PX domain-containing protein 2A, Adapter protein TKS5, Five SH3 domain-containing protein, SH3 multiple domains protein 1, Tyrosine kinase substrate with five SH3 domains, SH3PXD2A, FISH, KIAA0418, SH3MD1, TKS5

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SH3PXD2A Antibody (N-term) Blocking Peptide - Protein Information****Name** SH3PXD2A**Synonyms** FISH, KIAA0418, SH3MD1, TKS5**Function**

Adapter protein involved in invadopodia and podosome formation, extracellular matrix degradation and invasiveness of some cancer cells. Binds matrix metalloproteinases (ADAMs), NADPH oxidases (NOXs) and phosphoinositides. Acts as an organizer protein that allows NOX1- or NOX3-dependent reactive oxygen species (ROS) generation and ROS localization. In association with ADAM12, mediates the neurotoxic effect of amyloid-beta peptide.

**Cellular Location**

Cytoplasm. Cell projection, podosome. Note=Cytoplasmic in normal cells and localizes to podosomes in SRC- transformed cells

**Tissue Location**

Found in several cancer cell lines, particularly invasive breast carcinomas and melanomas

## **SH3PXD2A Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## **SH3PXD2A Antibody (N-term) Blocking Peptide - Images**

## **SH3PXD2A Antibody (N-term) Blocking Peptide - Background**

SH3PXD2A is required for podosome formation, degradation of the extracellular matrix, and for the invasiveness of some cancer cells. Binds phosphatidylinositol 3-phosphate (PtdIns(3)P) and phosphatidylinositol 3,4-biphosphate (PtdIns(3,4)P2). In association with ADAM12, mediates the neurotoxic effect of beta-amyloid peptide.

## **SH3PXD2A Antibody (N-term) Blocking Peptide - References**

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Laumet, G., et al. Neurosci. Lett. 468(1):1-2(2010)Crimaldi, L., et al. Exp. Cell Res. 315(15):2581-2592(2009)Voss, M., et al. BMC Immunol. 10, 53 (2009) :Gianni, D., et al. Sci Signal 2 (88), RA54 (2009) :